Kymera Therapeutics, Inc. has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD). The completion occurred nearly six months ahead of anticipated timelines, allowing the company to accelerate its expected topline data readout. Kymera now anticipates reporting data by year-end 2026, compared to the previous guidance of mid-2027. Following the announcement, shares of Kymera Therapeutics Inc. (NASDAQ: KYMR) climbed significantly, trading higher by more than 21% on Thursday.

The BROADEN2 trial evaluates KT-621, a first-in-class oral small molecule degrader medicine designed for immunological diseases. "With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent readouts, and NDA filing," said Nello Mainolfi, Founder, President, and CEO of Kymera Therapeutics.

Key Trial Milestones

Subject to regulatory discussions, Kymera expects to initiate Phase 3 trials for AD by mid-2027. Additionally, the company is conducting the BREADTH Phase 2b trial for asthma, with data expected in late 2027. The stock's current price of $121.03 is significantly above its moving averages, with the 20-day simple moving average (SMA) at $85.20, indicating a bullish trend. The Relative Strength Index (RSI) is currently at 84.74, suggesting that the stock is in overbought territory.

Kymera Therapeutics, Inc. has appointed Felix J. Baker, PhD, as Chairman of its Board of Directors, effective immediately. Dr. Baker succeeds Bruce Booth, DPhil, who served as Chairman since co-founding the company in 2016 and will remain an Independent Director. The leadership change comes as Kymera advances multiple mid- to late-stage programs and expands its oral degrader pipeline.

Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics, highlighted Dr. Baker's strategic contributions since joining the board in 2024. Dr. Baker has served as Kymera’s Lead Independent Director and is a Managing Member of Baker Brothers Investments, which he co-founded in 2000. He holds a BS and a PhD in Immunology from Stanford University and serves on the boards of several biopharmaceutical companies, including BeOne Medicines Ltd., Bicycle Therapeutics PLC, Kodiak Sciences, Inc., and Kiniksa Pharmaceuticals International, plc.

Dr. Booth was credited for guiding Kymera from an emerging technology to a clinical-stage organization. The company, founded in 2016, focuses on developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation (TPD) technology.

Board Composition

Kymera Therapeutics is a clinical-stage biotechnology company deploying TPD to address disease targets inaccessible with conventional therapeutics. The company has advanced the first degrader into the clinic for immunological diseases and aims to build an industry-leading pipeline of oral small molecule degraders.